<DOC>
	<DOCNO>NCT01839656</DOCNO>
	<brief_summary>The primary objective examine clinical efficacy multiple dos nusinersen ( ISIS 396443 ) administer intrathecally participant Infantile-Onset Spinal Muscular Atrophy ( SMA ) . The secondary objective examine safety tolerability multiple dos nusinersen administer intrathecally participant infantile-onset SMA examine cerebral spinal fluid ( CSF ) plasma Pharmacokinetics ( PK ) multiple dose nusinersen administer intrathecally participant infantile-onset SMA .</brief_summary>
	<brief_title>A Study Assess Efficacy , Safety Pharmacokinetics Nusinersen ( ISIS 396443 ) Infants With Spinal Muscular Atrophy ( SMA )</brief_title>
	<detailed_description>This study conduct protocol register Ionis Pharmaceuticals , Inc.. In August 2016 , sponsorship trial transfer Biogen .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Key Genetic documentation 5q SMA ( homozygous gene deletion mutation ) Onset clinical sign symptom consistent SMA ≥ 21 day &lt; 6 month ( 180 day ) age At study entry , receive adequate nutrition hydration ( without gastrostomy ) , opinion Site Investigator Body weight &gt; 5th percentile age use Center Disease Control Prevention ( CDC ) guideline Medical care meet expect continue meet guideline set Consensus Statement Standard Care SMA ( Wang et al . 2007 ) , opinion Site Investigator Gestational age 35 42 week gestation body weight ≥2 kg Reside within approximately 9 hour groundtravel distance participate study center duration study . Residence &gt; 2 hour groundtravel distance study center must obtain clearance Site Investigator study Medical Monitor Able complete study procedure , measurement visit parent guardian/participant adequately supportive psychosocial circumstance , opinion Site Investigator Key Hypoxemia ( O2 saturation awake &lt; 96 % O2 saturation asleep &lt; 96 % , without ventilation support ) Presence untreated inadequately treat active infection require systemic antiviral antimicrobial therapy time screen period History brain spinal cord disease would interfere lumbar puncture ( LP ) procedure , CSF circulation , safety assessment Presence implant shunt drainage cerebrospinal fluid ( CSF ) implant central nervous system ( CNS ) catheter History bacterial meningitis Clinically significant abnormality hematology clinical chemistry parameter , assess Site Investigator , screen would render participant unsuitable inclusion Treatment another investigational drug ( e.g. , albuterol , riluzole , carnitine , creatine , sodium phenylbutyrate , salbutamol , valproate , hydroxyurea etc ) , biological agent , device within 90 day prior enrollment anytime study . Any history gene therapy cell transplantation The participant parent ( ) legal guardian ( ) unable understand nature , scope , possible consequence study , agree comply protocol define schedule assessment Ongoing medical condition accord Site Investigator would interfere conduct assessment study . Examples medical disability SMA would interfere assessment safety would compromise ability participant undergo study procedure NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>210 Days</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>SMA</keyword>
	<keyword>SMN</keyword>
	<keyword>SMNRx</keyword>
	<keyword>ISIS-SMNRx</keyword>
	<keyword>ISIS 396443</keyword>
	<keyword>IONIS-SMNRx</keyword>
	<keyword>Spinraza</keyword>
</DOC>